Comparative Pharmacology
Head-to-head clinical analysis: BUSULFAN versus GLEOSTINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSULFAN versus GLEOSTINE.
BUSULFAN vs GLEOSTINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Busulfan is a bifunctional alkylating agent that crosslinks DNA, primarily at guanine N7 positions, leading to DNA strand breaks and inhibition of DNA replication and transcription. It is cell cycle phase-nonspecific.
GLEOSTINE (lomustine) is a nitrosourea alkylating agent that crosslinks DNA and RNA, inhibiting DNA synthesis and repair. It is cell cycle phase-nonspecific.
1-4 mg/day orally for remission induction in CML; 0.8-1 mg/kg every 6 hours orally for 4 days as part of myeloablative conditioning with cyclophosphamide.
130 mg/m2 orally every 6 weeks as a single dose; alternatively, 75 mg/m2 orally every 3 weeks.
None Documented
None Documented
Clinical Note
moderateBusulfan + Digoxin
"Busulfan may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateBusulfan + Digitoxin
"Busulfan may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateBusulfan + Deslanoside
"Busulfan may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateBusulfan + Acetyldigitoxin
"Busulfan may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 2.5 to 4 hours (mean ~2.6 hours) after oral administration; prolonged to 3-5 hours with high-dose regimens. Half-life may increase with hepatic impairment.
16-48 hours (terminal), with an active metabolite half-life of up to 5 days, requiring dose adjustment for renal impairment
Renal (10-50% unchanged), hepatic metabolism (primarily via glutathione S-transferases) with metabolites excreted in bile and urine. Fecal excretion minimal (<5%).
Renal: 60% (as metabolites), Fecal: <5% (unchanged and metabolites), Biliary: minimal
Category C
Category C
Alkylating Agent
Alkylating Agent